Cornercap Investment Counsel Inc Halozyme Therapeutics, Inc. Transaction History
Cornercap Investment Counsel Inc
- $329 Million
- Q3 2024
A detailed history of Cornercap Investment Counsel Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cornercap Investment Counsel Inc holds 8,007 shares of HALO stock, worth $392,343. This represents 0.14% of its overall portfolio holdings.
Number of Shares
8,007
Previous 28,211
71.62%
Holding current value
$392,343
Previous $1.48 Million
68.99%
% of portfolio
0.14%
Previous 0.25%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$863 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$632 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$325 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$199 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$167 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.83B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...